IMI AMR Accelerator

COMBINE
Part of IMI AMR Accelerator

COMBINE –

OPEN CALL for preclinical and clinical data sets

COMBINE is an IMI2 consortium, which supports the work of the IMI AMR Accelerator by identifying better ways to translate preclinical know-how into clinical practice and vice-versa. COMBINE will perform systematic cross-study analyses of relevant data sets originating from the AMR community, with the goal of improving the success of R&D efforts across the AMR community.

The COMBINE consortium is launching its first **OPEN CALL FOR DATA** to find partners worldwide that are willing to share data from **studies of prevention or treatment of bacterial infections**. The extended analyses we can perform using your data will help the AMR community to learn from the body of available science. **YOU** can help to prevent future failures and increase success rates of future developments by giving COMBINE access to data.

What are WE looking for?

Data from the study of medicines or candidate medicines for prevention or treatment of bacterial infections, e.g. **antibiotics, vaccines, monoclonal antibodies, pathoblockers and phages**.

We are specifically looking for

1.) Matched pairs of preclinical and clinical data (toxicology, PK/PD, efficacy)
2.) Data from clinical trials for prevention or treatment of bacterial infections

Data from **all relevant trials, both success and failures, are highly relevant** to derive the desired learnings.

www.amr-accelerator.eu

What pathogens are WE interested in?

ESCAPE pathogens such as ESBL positive *Escherichia coli* and *Clostridioides difficile*, as well as Neisseria *gonorrhoeae* and *Mycobacterium tuberculosis.*

Are YOU interested?

Contact us by 31 October 2020 at **AMR-data-technical.COMBINE@grit42.com to submit your Expression of Interest** or ask technical questions;
or at **AMRCOMBINEScientific@pei.de** to understand what type of analysis we could perform with your data sets

IMI AMR ACCELERATOR PARTNERS:

ASCLEPIA | BEAM ALLIANCE | BILL & MELINDA GATES FOUNDATION | BIOASTER | BIOCOM | BIOVERSYS | C-PATH | CHU DE POITIERS | CONSIGLIO NAZIONALE DELLE RICHERCHE | ÉCOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | ERASMUS MC UNIVERSITY | EVOTEC | FFUND | FORSCHUNGSZENTRUM BORSTEL | FOUNDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS | FRAUNHOFER GESELLSCHAFT | GRITSYSTEMS AS | GSK | HELMHOLTZ CENTRE FOR INFECTION RESEARCH | HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND | HOPITEAUX DE TOURS | IDMIT | IMABIOTECH | INSERM | INSTITUTE PASTEUR PARIS | INSTITUTE PASTEUR DE LILLE FOUNDATION | JANSSEN | LATVIA INSTITUTE OF ORGANIC SYNTHESIS | LEIDS UNIVERSITAIR MEDISCH CENTRUM | LYGATURE | MEDICAL UNIVERSITY OF VIENNA | MITOLOGICS | NHS | NICE | NOSOPHARM | PAUL-EHRLICH-INSTITUT | PUBLIC HEALTH ENGLAND | QPS NETHERLANDS | SCIENSANO | SERMAS | SKANE HOSPITAL LUND | STATENS SERUM INSTITUT | SYNAPSE | TB ALLIANCE | UNIVERSITE DE POITIERS | UNIVERSITE PARIS SORBONNE | UNIVERSITEIT LEIDEN | UNIVERSITET ANTWERPEN | UNIVERSITY CARLOS III MADRID | UNIVERSITY OF COPENHAGEN | UNIVERSITY OF DUNDEE | UNIVERSITY OF KÖLN | UNIVERSITY OF LIVERPOOL | UNIVERSITY OF PADOVA | UNIVERSITY OF PAVIA | UNIVERSITY OF ZARAGOZA | UPPSALA UNIVERSITET

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853967 | 853989 | 853979 | 853932 | 853800 | 853903 | 853976. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.